Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 218 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Food Effect cohort Clear all

Conditions: Healthy Volunteers
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neoplasms
Interventions: GSK3368715; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Philadelphia, Pennsylvania + 2 more

Conditions: Chronic Traumatic Brain Injury
Interventions: Anti-inflammatory Diet, N-acetyl Cysteine, Neuro Emotive Technique; Other · Dietary Supplement · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Villanova, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: Aes-103, Placebo; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Adult Subjects, Sickle Cell Disease
Interventions: FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Overland Park, Kansas

Conditions: Healthy
Interventions: AZD5847, Placebo to AZD5847; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: ZB716, Palbociclib; Drug
Lead sponsor: EnhancedBio USA Inc.; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen; Drug · Combination Product · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more

Conditions: Healthy Participants
Interventions: TBP-PI-HBr; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GNS-3545, GNS-3545 Placebo; Drug
Lead sponsor: Genosco Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Health Adult Subjects
Interventions: JPH034, Placebo Control; Drug · Other
Lead sponsor: J-Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Recurrent Genital Herpes Simplex Type 2
Interventions: ABI-1179, ABI-1179 Placebo; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Kansas City, Missouri • Rochester, New York • Seattle, Washington

Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Interventions: NMS-03597812; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: Duarte, California • Aurora, Colorado • Newark, Delaware + 4 more

Conditions: Plaque Psoriasis
Interventions: ASC50 tablets or matching placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers, Sjögren's Syndrome
Interventions: ASP5502, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Gout
Interventions: D-0120; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Plaque Psoriasis
Interventions: PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Dermatitis Hand, Skin Abnormalities, Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions: Hand sanitizer and hand washing; Other
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Type 2 Diabetes Mellitus
Interventions: BMF-219, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 36
States / cities: Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more

Conditions: Advanced Solid Tumors
Interventions: RO7623066, Olaparib, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more

Conditions: RSV Infection
Interventions: EDP-938, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteer
Interventions: BIIB145, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Inflammatory Bowel Disease
Interventions: TD-1473, Itraconazole; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

PET-MRI in Chronic Traumatic Brain Injury (CTBI)

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

Safety, Tolerability and Pharmacokinetics of FTX-6058

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants

A Study of JPH034 in Healthy Adult Participants

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Hand Sanitizer Effects on the Skin Barrier

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

A Study of EDP-938 in Healthy Subjects

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study